China Scientific Instruments & Materials Corporation (Sinopharm Scientific Instruments)

China Scientific Instruments & Materials Corporation (abbreviated as Sinopharm Scientific Instruments / CSIMC) is directly affiliated with China National Pharmaceutical Group Corporation (Sinopharm), China's largest pharmaceutical and health industry group, and is a core enterprise in the group's scientific instruments and medical devices sector. The company was established in June 1962; in 2009, it was restructured and incorporated into Sinopharm; in 2010, it was restructured with China Medical Devices Industry Corporation. Currently, its subsidiaries include China National Medical Devices Co., Ltd., China Scientific Instruments & Materials (Hong Kong) Co., Ltd., Sinopharm Group Financial Leasing Co., Ltd., Sinopharm Tepos (Beijing) Medical Engineering Technology Co., Ltd., and it holds shares in companies such as Hangwei GE Medical Systems Co., Ltd. Since its inception, CSIMC has always adhered to the purpose of providing specialized, integrated, and comprehensive services to a wide range of users, including medical institutions, research institutes, universities and colleges, and industrial and mining enterprises across the country, introducing advanced technologies and key equipment for national key scientific and technological projects such as the "863 Plan" and the "Torch Plan". As a core enterprise in Sinopharm's scientific instruments and medical devices business, relying on the group, the company currently conducts and plans to conduct: domestic commercial businesses, including consumables procurement agency services, GPO and government procurement, and direct sales of medical devices; industrial and scientific research businesses, including R&D, manufacturing of consumables and equipment, and value-added services such as maintenance; import and export businesses, including import and export of scientific instruments and medical devices; as well as bidding, government procurement, technical services, domestic and overseas exhibitions, property management, and other businesses. Its subsidiary, Sinopharm Medical Devices, is currently China's largest commercial enterprise in medical devices, boasting the largest commercial network for medical devices in China and having initially established a nationwide marketing network layout. CSIMC is further focusing on resource allocation, building a centralized management and control platform, and using Sinopharm Medical Devices as a business operation carrier to construct a strong-point, network-wide medical devices commercial network. Adhering to Sinopharm's corporate philosophy of "Caring for Life, Safeguarding Health", CSIMC and Sinopharm Medical Devices, which undertakes the national central reserve, allocation, and supply tasks for medical devices, provided various instruments, equipment, medical devices, and consumables during major national events such as the 1978 Tangshan earthquake, the 1998 flood relief, the 2003 fight against SARS, the 2008 Wenchuan earthquake relief, and the 2008 Olympics, playing a positive role in safeguarding people's life and health and maintaining social stability. CSIMC is a member enterprise of the China Council for the Promotion of International Trade, the China Chamber of International Commerce, and the six major national specialized import and export chambers of commerce (machinery and electronics, medical and health products, metals, minerals and chemicals, light industry, textiles, and cereals, oils and foodstuffs) as well as the Analytical Testing Association, and serves as the chairmanship unit of the China Scientific Instruments and Materials Production and Marketing Federation. CSIMC will fully implement the overall strategic layout of Sinopharm, driving the construction of the entire medical devices industry chain through the integration and large-scale development of the medical devices distribution industry, promoting the whole industry chain development with advantageous commercial business segments, stimulating industry with trade, promoting science with trade, continuously strengthening the full industry chain of trade, industry, science, and services in the medical devices sector, achieving leapfrog development, and making due contributions to national industrial integration and upgrading, the reform of the national medical and health system, and the smooth realization of Sinopharm's spectacular goals for the Twelfth Five-Year Plan. Since entering the "Twelfth Five-Year Plan" period, the company has actively promoted the upgrading and transformation of traditional business models, combining connotative development with denotative expansion, establishing a platform with reasonable resource allocation, value-added business services, and industrial development, centered on businesses such as agency import and export, bidding, foreign aid, government procurement, maintenance services, and financial leasing of scientific instruments and medical devices; establishing a medical devices logistics and distribution network that covers 30 provinces, municipalities, and autonomous regions nationwide and directly serves terminal medical institutions; and preliminarily forming a strategic layout radiating across the country of "One Platform, One Network, Full Industry Chain of Trade, Industry, Science, and Value-Added Services". Focusing on the long-term development of the national pharmaceutical and health industry, the company, leveraging its favorable government resources and market influence, is actively participating in the formulation of industry development plans and industrial standards, continuously promoting business innovation and resource integration, strengthening the construction of the full industry chain of trade, science, and industry, and striving to build China's largest scientific instruments and medical devices industry platform with industrial competitiveness and international influence."